Search research articles
Contact Us
Filters
Showing results (71-80 of 116) with videos related to
Page
of 12
Sort By:
Journal of Experimental & Clinical Cancer Research : CR
|
January 16, 2014
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
Maresa Altomonte, Anna Di Giacomo, Paola Queirolo, et al.
International Journal of Molecular Sciences
|
August 14, 2025
Assessing Determinants of Response to PARP Inhibition in Germline <i>ATM</i> Mutant Melanoma
Eleonora Allavena, Michela Croce, Bruna Dalmasso, et al.
Cancers
|
December 17, 2024
Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis
Francesca Consoli, Marco Tucci, Jacopo Pigozzo, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2025
Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis
Mario Mandalà, Filippo Ugolini, Lorenzo Caldirola, et al.
Cancers
|
January 21, 2022
The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts
Ignazio Stanganelli, Francesco Spagnolo, Giuseppe Argenziano, et al.
Frontiers in Oncology
|
February 27, 2023
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
Paolo A Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, et al.
International Journal of Molecular Sciences
|
December 23, 2022
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma
Lorenza Pastorino, Bruna Dalmasso, Eleonora Allavena, et al.
Cancer Treatment Reviews
|
June 5, 2018
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors
Luigia Stefania Stucci, Stella D'Oronzo, Marco Tucci, et al.
Cancer Management and Research
|
November 29, 2023
Characteristics of Real-World Patients with High-Risk <i>BRAF</i><sup>V600E/K</sup>-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
Pietro Quaglino, Paolo A Ascierto, Francesca Consoli, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 116) with videos related to
Sort By:
Page
of 12
Journal of Experimental & Clinical Cancer Research : CR
|
January 16, 2014
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
Maresa Altomonte, Anna Di Giacomo, Paola Queirolo, et al.
International Journal of Molecular Sciences
|
August 14, 2025
Assessing Determinants of Response to PARP Inhibition in Germline <i>ATM</i> Mutant Melanoma
Eleonora Allavena, Michela Croce, Bruna Dalmasso, et al.
Cancers
|
December 17, 2024
Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis
Francesca Consoli, Marco Tucci, Jacopo Pigozzo, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 13, 2025
Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis
Mario Mandalà, Filippo Ugolini, Lorenzo Caldirola, et al.
Cancers
|
January 21, 2022
The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts
Ignazio Stanganelli, Francesco Spagnolo, Giuseppe Argenziano, et al.
Frontiers in Oncology
|
February 27, 2023
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
Paolo A Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, et al.
International Journal of Molecular Sciences
|
December 23, 2022
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma
Lorenza Pastorino, Bruna Dalmasso, Eleonora Allavena, et al.
Cancer Treatment Reviews
|
June 5, 2018
Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors
Luigia Stefania Stucci, Stella D'Oronzo, Marco Tucci, et al.
Cancer Management and Research
|
November 29, 2023
Characteristics of Real-World Patients with High-Risk <i>BRAF</i><sup>V600E/K</sup>-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
Pietro Quaglino, Paolo A Ascierto, Francesca Consoli, et al.
Page
of 12